Cargando…

Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction

This research compared the incidence of adjacent segment pathology (ASP) between anterior interbody lumbar fusion (ALIF) treatment and transforaminal lumbar interbody fusion (TLIF) treatment. Seventy patients were included in this retrospective study: 30 patients received ALIF treatment, and 40 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Po-Kuan, Wu, Meng-Huang, Shih, Cheng-Min, Lin, Yen-Kuang, Chen, Kun-Hui, Pan, Chien-Chou, Huang, Tsung-Jen, Lee, Ching-Yu, Lee, Cheng-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708785/
https://www.ncbi.nlm.nih.gov/pubmed/34941644
http://dx.doi.org/10.3390/tomography7040072
_version_ 1784622772677246976
author Wu, Po-Kuan
Wu, Meng-Huang
Shih, Cheng-Min
Lin, Yen-Kuang
Chen, Kun-Hui
Pan, Chien-Chou
Huang, Tsung-Jen
Lee, Ching-Yu
Lee, Cheng-Hung
author_facet Wu, Po-Kuan
Wu, Meng-Huang
Shih, Cheng-Min
Lin, Yen-Kuang
Chen, Kun-Hui
Pan, Chien-Chou
Huang, Tsung-Jen
Lee, Ching-Yu
Lee, Cheng-Hung
author_sort Wu, Po-Kuan
collection PubMed
description This research compared the incidence of adjacent segment pathology (ASP) between anterior interbody lumbar fusion (ALIF) treatment and transforaminal lumbar interbody fusion (TLIF) treatment. Seventy patients were included in this retrospective study: 30 patients received ALIF treatment, and 40 patients received TLIF treatment at a single medical center between 2011 and 2020 with a follow-up of at least 12 months. The outcomes were radiographic adjacent segment pathology (RASP) and clinical adjacent segment pathology (CASP). The mean follow-up period was 42.10 ± 22.61 months in the ALIF group and 56.20 ± 29.91 months in the TLIF group. Following single-level lumbosacral fusion, ALIF is superior to TLIF in maintaining lumbar lordosis, whereas the risk of adjacent instability in the ALIF group is significantly higher. Regarding ASP, the incidence of overall RASP and CASP did not differ significantly between ALIF and TLIF groups.
format Online
Article
Text
id pubmed-8708785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87087852021-12-25 Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction Wu, Po-Kuan Wu, Meng-Huang Shih, Cheng-Min Lin, Yen-Kuang Chen, Kun-Hui Pan, Chien-Chou Huang, Tsung-Jen Lee, Ching-Yu Lee, Cheng-Hung Tomography Article This research compared the incidence of adjacent segment pathology (ASP) between anterior interbody lumbar fusion (ALIF) treatment and transforaminal lumbar interbody fusion (TLIF) treatment. Seventy patients were included in this retrospective study: 30 patients received ALIF treatment, and 40 patients received TLIF treatment at a single medical center between 2011 and 2020 with a follow-up of at least 12 months. The outcomes were radiographic adjacent segment pathology (RASP) and clinical adjacent segment pathology (CASP). The mean follow-up period was 42.10 ± 22.61 months in the ALIF group and 56.20 ± 29.91 months in the TLIF group. Following single-level lumbosacral fusion, ALIF is superior to TLIF in maintaining lumbar lordosis, whereas the risk of adjacent instability in the ALIF group is significantly higher. Regarding ASP, the incidence of overall RASP and CASP did not differ significantly between ALIF and TLIF groups. MDPI 2021-12-02 /pmc/articles/PMC8708785/ /pubmed/34941644 http://dx.doi.org/10.3390/tomography7040072 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Po-Kuan
Wu, Meng-Huang
Shih, Cheng-Min
Lin, Yen-Kuang
Chen, Kun-Hui
Pan, Chien-Chou
Huang, Tsung-Jen
Lee, Ching-Yu
Lee, Cheng-Hung
Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
title Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
title_full Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
title_fullStr Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
title_full_unstemmed Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
title_short Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
title_sort comparison of incidence of adjacent segment pathology between anterior lumbar interbody fusion and transforaminal lumbar interbody fusion treatments for lumbosacral junction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708785/
https://www.ncbi.nlm.nih.gov/pubmed/34941644
http://dx.doi.org/10.3390/tomography7040072
work_keys_str_mv AT wupokuan comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT wumenghuang comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT shihchengmin comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT linyenkuang comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT chenkunhui comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT panchienchou comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT huangtsungjen comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT leechingyu comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction
AT leechenghung comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction